Led · Equity · May 2026

H1 is a nine-year-old healthcare data platform that compiles and sells detailed information about physicians to pharma companies, hospital systems, and health insurers. The company emphasizes that its core asset is proprietary provider data, which it views as difficult for AI models to replicate and potentially valuable to AI model makers. H1 turned cash flow and EBITDA profitable last year and is forecasting more than 40% growth this year. The startup has grown organically and through acquisitions of smaller competitors and complementary businesses. H1 raised $100 million led by Altimeter Capital in November 2021 at a $750 million valuation. The recent investment by CVS Health Ventures establishes a strategic partnership with a major healthcare company.

Led · Series C · Feb 2026

Codoxo offers a Generative AI-powered Unified Cost Containment Platform that spans the entire claim lifecycle, with its flagship Point Zero Payment Integrity model intervening before claims are even submitted. By combining proactive provider education, data mining, clinical chart review, deepfake detection, and policy-to-code automation, the platform reduces downstream denials and overpayments while strengthening payer–provider relationships. The company supports payment integrity operations across more than 80 million covered lives and reports 100 % customer retention and 125 % net revenue retention for 2025. Customer implementations have delivered $12–$16 PMPY in savings at the pre-claim stage and up to $66 PMPY across the broader payment spectrum. Codoxo has earned recognition from Inc. 5000, Everest Group, Black Book Research, and the A.I. Awards, underscoring its category leadership. Recent product launches include the Data Health Integrity Agent and generative-AI-driven Policy-to-Code capabilities. With continued compliance achievements such as NIST 800-53 Rev 5 and HITRUST r2 certification, Codoxo is positioning itself for accelerated national expansion.

Participated · Equity · Feb 2026

Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Led · Equity · Oct 2025

knownwell delivers evidence-based obesity treatment that combines metabolic health services, primary care, nutrition counseling, and behavioral health, all covered by insurance and offered virtually nationwide and at select physical clinics. Its physician-designed care model emphasizes respectful, longitudinal engagement, producing a >90 net promoter score, 91% one-year patient retention, and 93% sustained weight loss after one year. Over the last 18 months the company has expanded from Massachusetts into Georgia, Illinois, and Texas while activating virtual care in all 50 states. This approach targets a market in which obesity drives more than $260 billion in annual U.S. healthcare costs. Management views payer and health-system alignment as critical and positions knownwell as a scalable, value-based partner for those stakeholders. The company has now raised more than $50 million in total funding, including the latest $25 million round, to fuel further geographic growth and platform development.

Participated · Series D · Sep 2025

Founded in 2020, Thyme Care builds an integrated oncology infrastructure that aligns payers, providers, employers, and patients around value-based care. Its technology stack combines AI-driven orchestration, advanced data analytics, and a virtual/hybrid care team of doctors, nurses, social workers, and care partners to guide patients through every stage of the cancer journey. The company now partners with more than 1,000 oncologists and reaches 8 million covered lives, managing over $5 billion in oncology spend. Outcomes include 90% of members feeling more supported, 72% proactively submitting ePRO updates, 40% fewer ER visits, and 19% fewer hospital admissions among engaged members. One partner practice saved nearly 2,000 staff hours in a year, underscoring efficiency gains. Thyme Care achieved profitability ahead of its Series D raise, demonstrating a sustainable business model. Looking forward, the company plans to deepen AI integration to automate documentation, surface real-time insights, and eliminate additional bottlenecks in cancer care. By scaling these capabilities, Thyme Care aims to serve as the backbone for more connected, accountable, and compassionate oncology care nationwide.